T2DM (Type 2 Diabetes Mellitus)
Conditions
Brief summary
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.
Interventions
DRUGChiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 1.
DRUGChiglitazar tablet, dose 1
Chiglitazar tablet administered as one of the reference treatment at dose level 1.
DRUGMetformin extended-release tablet, dose 1
Metformin extended-release tablet administered as one of the reference treatment at dose level 1.
DRUGChiglitazar/Metformin extended-release fixed-dose combination tablet, dose 2
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 2.
DRUGChiglitazar tablet, dose 2
Chiglitazar tablet administered as one of the reference treatment at dose level 2.
DRUGMetformin extended-release tablet, dose 2
Metformin extended-release tablet administered as one of the reference treatment at dose level 2.
Sponsors
Chipscreen Biosciences, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female participants； * Age from 18 to 45 years, inclusive； * Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg； * From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures； * Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion criteria
* Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders; * Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products; * Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism; * Surgery within 3 months prior to screening or planned surgery during the study period; * Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period; * History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose; * Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation; * Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment; * History of drug or substance abuse, or a positive alcohol or urine drug screening test; * Intolerance to venipuncture, or a history of fainting in response to needles or blood; * Fasting blood glucose \> 6.1 mmol/L or \< 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope; * Participation in any interventional clinical trial within 3 months prior to screening; * Blood donation or significant blood loss (\> 200 mL) within 3 months prior to screening; * Pregnant or lactating women; * Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study; * Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study; * Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose; * Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose; * Glomerular Filtration Rate (GFR) \< 90 mL/min/1.73 m²; * Systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure \< 50 mmHg or ≥ 90 mmHg at screening; * A positive test result at screening for any of the following: Human Immunodeficiency Virus antibody, Treponema pallidum antibody, Hepatitis B surface antigen, or Hepatitis C virus antibody; * Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing; * Plans to or is required to engage in strenuous physical activity or exercise during the study period; * Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum plasma concentration (Cmax) | Pre-dose and at multiple timepoints post-dose up to 72 hours |
| Area Under the Plasma Concentration-Time Curve from time zero to the last measurable concentration (AUC0-last) | Pre-dose and at multiple timepoints post-dose up to 72 hours |
| Area Under the Plasma Concentration-Time Curve from time zero to infinity (AUC0-∞) | Pre-dose and at multiple timepoints post-dose up to 72 hours |
Secondary
| Measure | Time frame |
|---|---|
| Time to Maximum Plasma Concentration（Tmax） | Pre-dose and at multiple timepoints post-dose up to 72 hours |
| Elimination Half-life （t1/2） | Pre-dose and at multiple timepoints post-dose up to 72 hours |
| Apparent Total Clearance （CL/F） | Pre-dose and at multiple timepoints post-dose up to 72 hours |
| Apparent Volume of Distribution during the terminal phase （Vz/F） | Pre-dose and at multiple timepoints post-dose up to 72 hours |
| Incidence of Adverse Events (AEs) | up to Day 11 |
Outcome results
None listed